Published On: Wed, Oct 19th, 2016

Current Price Targets For Illumina, Inc. (NASDAQ:ILMN)


Recently stock market analysts have updated their consensus ratings on shares of Illumina, Inc. (NASDAQ:ILMN).

Most recent broker ratings

10/13/2016 – Illumina, Inc. had its “buy” rating reiterated by analysts at Argus. They now have a USD 170 price target on the stock.

10/11/2016 – Illumina, Inc. had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 142 price target on the stock.

10/11/2016 – Illumina, Inc. had its “market perform” rating reiterated by analysts at Wells Fargo. They now have a USD 137.5 price target on the stock.

10/11/2016 – Illumina, Inc. had its “neutral” rating reiterated by analysts at BTIG Research.

10/11/2016 – Illumina, Inc. was downgraded to “sell” by analysts at Janney Montgomery Scott. They now have a USD 125 price target on the stock.

10/11/2016 – Illumina, Inc. was downgraded to “neutral” by analysts at Citigroup. They now have a USD 140 price target on the stock.

10/11/2016 – Illumina, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 160 price target on the stock.

10/11/2016 – Illumina, Inc. had its “hold” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 155 price target on the stock.

10/11/2016 – Illumina, Inc. had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 135 price target on the stock.

08/22/2016 – Illumina, Inc. was downgraded to “neutral” by analysts at CL King.

07/27/2016 – Illumina, Inc. had its “neutral” rating reiterated by analysts at Mizuho. They now have a USD 148 price target on the stock.

07/27/2016 – Illumina, Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 180 price target on the stock.

07/14/2016 – Illumina, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 161 price target on the stock.

07/05/2016 – Illumina, Inc. was downgraded to “underweight” by analysts at Morgan Stanley. They now have a USD 110 price target on the stock.

05/04/2016 – Illumina, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 160 price target on the stock.

Illumina, Inc. has a 50 day moving average of 169.54 and a 200 day moving average of 155.73. The stock’s market capitalization is 21.29B, it has a 52-week low of 127.10 and a 52-week high of 196.47.

The share price of the company (NASDAQ:ILMN) was up +2.83% during the last trading session, with a high of 149.32 and the volume of Illumina, Inc. shares traded was 2517647.

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.